DnaK Therapeutics
01 / AboutFounded 2024 · Research from 2011

The company is two years old.
The research is fifteen.

2011Research begins at IHV
2024Incorporated, UMB
technology transfer
2025Joins USF CONNECT
in January
2026GATC Health
collaboration

History

DnaK Therapeutics was incorporated in 2024 to commercialize research that started in 2011.

That year, at the Institute of Human Virology at the University of Maryland, Baltimore, Dr Robert C. Gallo, Dr Davide Zella and Dr Francesca Benedetti began looking at how the human microbiota interacts with host cells. What they found was that a chaperone protein made by tumor-associated bacteria, DnaK, suppresses p53, obstructs DNA repair, and undercuts the chemotherapy drugs that rely on p53.

Ten peer-reviewed papers have come out of that work between 2018 and 2026, three of them in the Proceedings of the National Academy of Sciences. In 2024 the research was transferred out of the University of Maryland, Baltimore, and the company was formed around it.

Where we are

Since January 2025 the company has worked out of USF CONNECT, the University of South Florida's Tampa Bay Technology Incubator, which provides laboratory space, shared facilities, mentorship and business support.

The preclinical program is supported in part by a 2025 research award from the Casey DeSantis Florida Cancer Innovation Fund, administered by the Florida Department of Health, which funds cancer research innovation in the state. The award supports the two lines of work described on the pipeline page: inhibitors of bacterial DnaK intended to restore sensitivity to chemotherapy, and an assay that measures DnaK to identify the patients most likely to benefit from them.

Intellectual property

The approach is covered by filings in the United States, India and internationally. We state status, not valuation.

  • WO 2023/196891 A2, Methods of Treating Cancer by Inhibiting Bacterial DnaK Activities of Anti-Cancer Drugs, PCT application
  • US Publication No. 2025-0281456, published 11 September 2025
  • India, national phase filing
02 / CompanyDetails
Legal entityDnaK Therapeutics, Inc.
Founded2024
StagePreclinical
LocationUSF CONNECT, 3802 Spectrum Blvd., Suite 128P, Tampa, FL 33612
General enquiriesinfo@dnaktherapeutics.com